BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27138569)

  • 1. Checkpoint inhibitors and gastrointestinal immune-related adverse events.
    Pernot S; Ramtohul T; Taieb J
    Curr Opin Oncol; 2016 Jul; 28(4):264-8. PubMed ID: 27138569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
    Cramer P; Bresalier RS
    Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.
    Reddy HG; Schneider BJ; Tai AW
    Clin Transl Gastroenterol; 2018 Sep; 9(9):180. PubMed ID: 30228268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
    Carbonnel F; Soularue E; Coutzac C; Chaput N; Mateus C; Lepage P; Robert C
    Semin Immunopathol; 2017 Apr; 39(3):327-331. PubMed ID: 28093620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitor-Induced Colitis.
    Bellaguarda E; Hanauer S
    Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review: colitis associated with anti-CTLA-4 therapy.
    Gupta A; De Felice KM; Loftus EV; Khanna S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing immune checkpoint-blocking antibody side effects.
    Postow MA
    Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
    Antoun J; Titah C; Cochereau I
    Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
    Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
    Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
    Siakavellas SI; Bamias G
    Curr Opin Gastroenterol; 2018 Nov; 34(6):377-383. PubMed ID: 30157044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
    Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
    Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.
    Samaan MA; Pavlidis P; Papa S; Powell N; Irving PM
    Nat Rev Gastroenterol Hepatol; 2018 Apr; 15(4):222-234. PubMed ID: 29512649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune-related adverse events by immune checkpoint inhibitors].
    Kadono T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
    Wang Y; Wiesnoski DH; Helmink BA; Gopalakrishnan V; Choi K; DuPont HL; Jiang ZD; Abu-Sbeih H; Sanchez CA; Chang CC; Parra ER; Francisco-Cruz A; Raju GS; Stroehlein JR; Campbell MT; Gao J; Subudhi SK; Maru DM; Blando JM; Lazar AJ; Allison JP; Sharma P; Tetzlaff MT; Wargo JA; Jenq RR
    Nat Med; 2018 Dec; 24(12):1804-1808. PubMed ID: 30420754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.